Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomerica, Inc. stock logo
BMRA
Biomerica
$3.15
+3.6%
$3.30
$1.93
$10.16
$8.03M0.35282,616 shs28,657 shs
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
$2.25
+2.3%
$2.17
$1.30
$15.59
$8.10M0.18848,418 shs43,389 shs
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$0.36
+0.3%
$0.35
$0.29
$2.69
$8.33M1.35278,852 shs51,139 shs
VGLS
VG Life Sciences
$0.00
$0.00
$0.00
$0.00
$2.11M1.673.95 million shs13.10 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomerica, Inc. stock logo
BMRA
Biomerica
-1.49%-8.72%-6.72%-11.18%+4.25%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
+3.29%-5.17%-3.51%+53.85%+973.17%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-0.58%-1.21%+4.61%+4.61%-85.82%
VGLS
VG Life Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomerica, Inc. stock logo
BMRA
Biomerica
1.508 of 5 stars
0.05.00.00.03.30.80.6
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/AN/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
3.3947 of 5 stars
2.85.00.00.03.32.51.3
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomerica, Inc. stock logo
BMRA
Biomerica
0.00
N/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
0.00
N/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
1.50
Reduce$0.4525.07% Upside
VGLS
VG Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomerica, Inc. stock logo
BMRA
Biomerica
$5.41M1.48N/AN/A$3.13 per share1.01
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/A($0.37) per shareN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$19.31M0.43N/AN/A$1.36 per share0.26
VGLS
VG Life Sciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomerica, Inc. stock logo
BMRA
Biomerica
-$5.98M-$2.32N/AN/A-85.42%-85.90%-61.06%8/26/2025 (Estimated)
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
-$1.98MN/A0.00N/AN/AN/AN/A8/15/2025 (Estimated)
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$70.84M-$2.73N/AN/AN/AN/A-162.79%-124.10%8/13/2025 (Estimated)
VGLS
VG Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A

Latest VGLS, TSBX, NLSP, and BMRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.16N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.26-$0.51-$0.25-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomerica, Inc. stock logo
BMRA
Biomerica
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/AN/AN/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/AN/AN/AN/AN/A
VGLS
VG Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A
3.76
2.76
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A
2.69
2.69
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/A
3.70
3.70
VGLS
VG Life Sciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biomerica, Inc. stock logo
BMRA
Biomerica
22.28%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
N/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
52.51%
VGLS
VG Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
Biomerica, Inc. stock logo
BMRA
Biomerica
15.00%
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
16.40%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
32.10%
VGLS
VG Life Sciences
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomerica, Inc. stock logo
BMRA
Biomerica
602.55 million2.16 millionOptionable
NLS Pharmaceutics Ltd. stock logo
NLSP
NLS Pharmaceutics
63.60 million3.01 millionNot Optionable
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
8223.14 million15.71 millionNot Optionable
VGLS
VG Life Sciences
121.10 billionN/ANot Optionable

Recent News About These Companies

VGLS VG Life Sciences Inc. - Seeking Alpha
VG Life Sciences Inc.
VG Life Sciences, Inc. Increases Authorized Shares
VG Life Sciences Inc. (VGLS)
VG Life Sciences Inc VGLS
Report warns of 'oversupply' of life sciences real estate
VGLS VG Life Sciences Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomerica stock logo

Biomerica NASDAQ:BMRA

$3.15 +0.11 (+3.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.14 -0.01 (-0.32%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NLSP

$2.25 +0.05 (+2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$2.25 0.00 (0.00%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Turnstone Biologics stock logo

Turnstone Biologics NASDAQ:TSBX

$0.36 +0.00 (+0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.22%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

VG Life Sciences OTCMKTS:VGLS

$0.0001 0.00 (0.00%)
As of 07/15/2025 12:47 PM Eastern

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.